A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 versus Standard of Care (Liposomal Amphotericin B followed by Voriconazole) for Early Antifungal Therapy of Suspected Invasive Mould Infections
Not yet recruitingCTIS2025-522835-32-00
Elion Therapeutics Inc.Suspected Invasive Mould Infection
Target: 54Updated: 2026-02-27